MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
Story updates
12:10:24 PM UTC
SquawkNews
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.